Asia-Pacific biopharma is no longer just about big numbers on paper. This year, BioPharma APAC’s 2026 ranking of the top 10 deals shows a sharp split between headline values and real money on the table. Seven licensing and tech transfer deals claimed a total of $54.4 billion in value. Only $4.5 billion of that was guaranteed up front. The three biggest M&A deals, on the other hand, brought $16 billion in fully committed capital. That’s where the real power sits.
In September 2026, Sun Pharma began refinancing its Organon acquisition by planning a 100 billion rupee (about $1.04 billion) rupee bond issue to partially repay a bridge loan, following the earlier syndication of an 18-month $12 billion loan.
South Korea’s strategic moves in the spotlight
Samsung Biologics made a bold move. Its $1.8 billion buyout of Switzerland’s PolyPeptide Group, ranked sixth, is a clear bet on the future of peptide drugs. Demand for obesity and diabetes treatments is rising fast. Samsung wants to lock in peptide CDMO capacity and supply chains now. Industry reports put the deal’s value at about 2.7 billion Swiss francs, or 2.7 trillion won. That makes it one of Korea’s biggest M&A deals this year, according to SEDaily English.
SK Biopharm came in seventh. It licensed the epilepsy drug candidate "ofacalim" from Biohaven for $795 million. The upfront payment was unusually high for a Korean firm. This shows Korean companies are now willing to pay U.S.-level prices for promising assets, even before key clinical data is in.
On October 2, 2026, PolyPeptide Group called an extraordinary general meeting of shareholders in response to a public offer from Samsung Peptide AG, a subsidiary of Samsung Biologics, confirming the Korean side is acting through this special legal entity.
Deal structures and shifting power dynamics
One deal didn’t make the cut. The Alteogen-Novartis agreement, with up to $3.223 billion in milestones, fell short because the upfront payment was not disclosed. BioPharma APAC’s ranking system penalizes deals that hide or skip guaranteed capital. Companies are now rethinking how they build and reveal their deals.
Asian firms are no longer just targets for Western buyers. Four of the top deals—Sun Pharma, Samsung Biologics, SK Biopharm, and Japan’s Shionogi—involved Asian companies buying U.S. or European assets. Western firms still buy a lot of Asian tech, but the balance is shifting. Chinese companies like Hengrui Pharmaceuticals, Innovent, and Dizal Pharmaceuticals are also changing the game. They’re pushing for new deal structures and tougher terms on price and contracts.
Beyond the numbers: what this means for biopharma
Asia-Pacific biopharma is now an active force in global deals. South Korea’s rise in tech transfer and M&A is part of a bigger trend. As shown in earlier coverage, companies in the region are moving fast. They’re going beyond small partnerships. Now, they’re making bold, expensive moves that change the competitive map.
This is a turning point. Asian biopharma is setting the pace. These companies are putting up real money, buying global assets, and negotiating as equals with Western giants. The old rules are gone. For anyone watching the industry, one thing is clear. Asia-Pacific biopharma is done playing a supporting role. The next wave of innovation and investment will come from those who can back up their plans with cash and a clear strategy.
